Induced Pluripotent Stem Cells
We are setting a new standard with well-characterized induced pluripotent stem cell (iPSC) lines that are suitable for research, clinical and commercial use.
Accelerating the development of iPSC-derived immunotherapies and regenerative medicines.
An Integrated Ecosystem to Spur Discovery
Induced pluripotent stem cells (iPSCs) have the potential for unlimited proliferation and the ability to differentiate into any cell type, offering tremendous potential to treat disease directly at the source. Our iPSC platform provides the foundation to translate well-characterized cell lines into transformational medicines in regenerative medicine and immuno-oncology.
Setting a New Standard in iPSCs
At ElevateBio®, we are accelerating the development of iPSC-derived therapeutics. Our next-generation iPSC lines are produced in stroma-free, xeno-free, and serum-free conditions and are suitable across for research, clinical, and commercial use. We are setting a new standard with iPSCs that can accelerate timelines and reduce manufacturing risks, regulatory hurdles, and costs in the development of iPSC-derived therapies for our internal and partner programs.
Developing iPSC-Derived Allogeneic Immune Therapies
In collaboration with George Daley, M.D, Ph.D. and Boston Children’s Hospital, ElevateBio established a new company to develop off-the-shelf immune therapies derived from induced pluripotent stem cells (iPSCs). The company is founded upon a novel differentiation process that develops iPSCs into mature immune cells, which was detailed in a peer-reviewed publication in Cell Stem Cell. This new company is enabled by our iPSC and gene editing technologies and scale-up manufacturing capabilities to develop a broad pipeline of iPSC-derived therapies.
Our Integrated Technology Platforms: Fueling the Discoveries of Tomorrow
Gene Editing
We have a powerful suite of proprietary gene editing technologies to accelerate the development of life-changing and curative therapies for patients. Click here to learn about gene editing.
RNA, Cell, Protein, and Vector Engineering
We have centralized RNA, cell, protein, and vector engineering to improve productivity and scalability and to ensure external partners and internal programs have access to the necessary tools to build novel therapies. Click here to learn about engineering.
Partner with ElevateBio®
Wherever you are in your cell and gene therapy product lifecycle, we can strengthen and accelerate the development of your transformative therapies with our enabling technologies unmatched manufacturing capabilities.